- Home
- ESGL vs SPRO Comparison
ESGL vs SPRO Comparison
Compare ESGL & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESGL
- SPRO
- Stock Information
- Founded
- ESGL 1999
- SPRO 2013
- Country
- ESGL Singapore
- SPRO United States
- Employees
- ESGL N/A
- SPRO N/A
- Industry
- ESGL
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- ESGL
- SPRO Health Care
- Exchange
- ESGL Nasdaq
- SPRO Nasdaq
- Market Cap
- ESGL 52.2M
- SPRO 49.6M
- IPO Year
- ESGL N/A
- SPRO 2017
- Fundamental
- Price
- ESGL $1.05
- SPRO $0.88
- Analyst Decision
- ESGL
- SPRO Buy
- Analyst Count
- ESGL 0
- SPRO 4
- Target Price
- ESGL N/A
- SPRO $5.00
- AVG Volume (30 Days)
- ESGL 19.5K
- SPRO 282.6K
- Earning Date
- ESGL 03-03-2025
- SPRO 03-12-2025
- Dividend Yield
- ESGL N/A
- SPRO N/A
- EPS Growth
- ESGL N/A
- SPRO N/A
- EPS
- ESGL N/A
- SPRO 0.06
- Revenue
- ESGL $6,218,838.00
- SPRO $106,455,000.00
- Revenue This Year
- ESGL N/A
- SPRO N/A
- Revenue Next Year
- ESGL N/A
- SPRO N/A
- P/E Ratio
- ESGL N/A
- SPRO $13.50
- Revenue Growth
- ESGL 20.34
- SPRO 37.01
- 52 Week Low
- ESGL $0.41
- SPRO $0.83
- 52 Week High
- ESGL $2.23
- SPRO $1.89
- Technical
- Relative Strength Index (RSI)
- ESGL 33.04
- SPRO 34.84
- Support Level
- ESGL $1.20
- SPRO $0.86
- Resistance Level
- ESGL $2.09
- SPRO $0.94
- Average True Range (ATR)
- ESGL 0.19
- SPRO 0.07
- MACD
- ESGL -0.02
- SPRO -0.01
- Stochastic Oscillator
- ESGL 2.81
- SPRO 10.80
About ESGL ESGL Holdings Limited
ESGL Holdings Ltd Formerly Environmental Solutions Group Holdings Ltd is a waste management, treatment and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical and electroplating companies.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.